Prostate cancer is highly sensitive to androgenic stimulation. Testosterone—and more potently, its derivative dihydrotestosterone (DHT)—binds to the androgen receptor (AR) in prostate cells, which can drive the growth and survival of both normal and malignant cells.
Castration-Resistant Prostate Cancer (CRPC):
Even after testosterone levels are medically reduced, some prostate cancers continue to thrive by adapting their AR pathway. CRPC often signals a transition to a more aggressive, treatment-resistant state.
(Will delete Record if Target field = "Delete") Home